# Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

> **NCT04551131** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 10 (actual)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04551131
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-13
- **Primary completion:** 2025-11-07
- **Final completion:** 2026-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- Incyte Corporation
- North American Consortium for Histiocytosis
- Cures Within Reach

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551131, "Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04551131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*